论文部分内容阅读
充血性心力衰竭的患病率在全世界范围内持续上升,严重威胁着人们的生命健康。大量的研究表明细胞内钙离子代谢失调是心肌衰竭的主要生物化学标志,因此对心肌细胞内钙离子循环进行干预是治疗充血性心力衰竭的一种极富希望的方法。Istaroxime是一种新型正性肌力药物,它既可通过抑制钠钾三磷酸腺苷酶,增加细胞内游离钙离子浓度来实现其正性收缩作用,同时还可以通过提高肌浆网钙离子三磷酸腺苷酶的活性,加速细胞内游离钙离子清除而发挥正性舒张的作用。目前的研究显示istar-oxime是一种安全有效的正性肌力药物。
The prevalence of congestive heart failure in the world continued to rise, a serious threat to people’s lives and health. Numerous studies have shown that the imbalance of intracellular calcium metabolism is the major biochemical marker of myocardial failure. Therefore, intervening calcium circulation in cardiomyocytes is a promising method for the treatment of congestive heart failure. Istaroxime is a new type of inotropic agent, which can not only through the inhibition of sodium and potassium adenosine triphosphates, increased intracellular free calcium concentration to achieve its positive contractility, but also by increasing the sarcoplasmic reticulum calcium ATPase activity , Accelerate the intracellular free calcium ions play a positive role in diastolic. The current study shows that istar-oxime is a safe and effective inotropic agent.